Q-omics provides the consensus-scored IGSF10 profile across patient tissues and cancer cell-line models. IGSF10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IGSF10 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, IGSF10 RNA expression shows 16,067 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where IGSF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGSF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGSF10 survival associations across molecular data types. IGSF10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGSF10 RNA expression–survival associations across cancer types. High IGSF10 expression shows unfavorable associations in KICH, BLCA, UCEC and LGG, but favorable associations in BRCA and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for IGSF10 RNA expression.
This table summarizes IGSF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGSF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGSF10 shows lower tumor expression in KIRC, THCA, BLCA, COAD, LUAD and LUSC. The KIRC box plot shows higher IGSF10 RNA expression in normal versus tumor tissue (log2 FC = −0.802, t-test p < 0.001).
This table shows molecular features associated with IGSF10 in patient tissues and cancer cell lines. In patient samples, IGSF10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGSF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
